Press Releases

Presentation Scheduled on February 23, 2017 at 10:00 AM ET

Presentation Scheduled on Monday, February 13th, 2017 at 11:00 am ET

Presentation Scheduled on Tuesday, January 31, 2017 at 11:00 am ET

Resubmission of Twirla ® New Drug Application Expected to Address FDA's Complete Response Letter Company Plans to Resubmit NDA in First Half of 2017              Company to Host Conference Call on January 3, 2017 at 5:00 p.m. Eastern Time                PRINCETON, N.J., Jan.

Presentation Scheduled on Monday, January 9, 2017 at 9:00 AM Pacific Time

Presentation Scheduled on Thursday, January 12th, 2017 at 11:30 AM Pacific Time

PRINCETON, N.J., Dec. 01, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical company announced today that it has received net proceeds of approximately $3 million in non-dilutive financing through the State of New Jersey's Technology Business

Top-Line Data Expected in Early January 2017; Resubmission Planned for First Half 2017  Cash Expected to Fund Operations Through the End of 2017 PRINCETON, N.J., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical company, today

Twirla® Clinical Trial Expected to Complete in Fourth Quarter 2016 and Resubmission Planned for First Half 2017; Cash Expected to Fund Operations Through the End of 2017

Industry Veteran Brings Significant Management and Commercial Experience